Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by subaru1ion Oct 03, 2023 5:19pm
130 Views
Post# 35667840

RE:RE:Subaru1, before I head out, Mr. Pidduck clearly used the

RE:RE:Subaru1, before I head out, Mr. Pidduck clearly used the Fair enough but the CEO also mentioned their inability to reveal their "traditional global pharmaceutical partner" FOR COMPETITIVE REASONS.

Those last three words indicates very clearly commercial development that is not yet available to be released publicly.    You can go back and check out that fact for yourself by listening towards the end of one of the conference calls of late 2022 or early 2023.   

And that okgonow is a recorded fact and one needs to correlate that statement to another statement made on the public of "over 20 strong clinical trials, many in late stage".

This to me is an indication that they have been working with their global pharma partner for quite some time, perhaps several years from the past.  That you can extrapolate from 'many in late stage' if you can approximate how long it takes for Stage 1 and Stage 2 clinical trials to be completed before going Stage 3.  

So we are trying to keep it 'very real' based on FACTS disclosed publicly to us as shareholders by the CEO and other members of senior managment.  

Have a wonderful evening, Peace and Tranquility π.


<< Previous
Bullboard Posts
Next >>